perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295295;](https://doi.org/10.1101/2023.09.09.23295295) this version posted September 11, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

Lifelong impacts ofpuberty timing on human plasma metabolic

profiles

- 3 Zengjun Li, MB¹; Si Fang, MS^{2, 3}; Dong Liu, MPH⁴; Fei Li*, MD^{4, 5, 6}, Cairong
- **Zhu* , PhD¹; Jian Zhao* , PhD4, ⁶**

Affiliations:

- 1. Department of Epidemiology and Biostatistics, West China School of Public Health
- and West China Fourth Hospital, Sichuan University, 610041, China.
- 2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol,
- United Kingdom.
- 3. Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), University
- of Bristol, Bristol, United Kingdom.
- 4. Ministry of Education and Shanghai Key Laboratory of Children's Environmental
- Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine,
- Shanghai, 200092, China
- 5. Department of Developmental and Behavioral Pediatric & Child Primary Care,
- Brain and Behavioral Research Unit of Shanghai Institute for Pediatric Research,
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,

China

- 6. Department of Maternal and Child Health, School of Public Health, Shanghai Jiao
- Tong University, 200092, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

***Corresponding author:**

- Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of
- Medicine, Shanghai, 200092, China (jzhao.epi@gmail.com).
- Dr Cairong Zhu, Department of Epidemiology and Biostatistics, West China School
- of Public Health and West China Fourth Hospital, Sichuan University, 610041, China
- (cairong.zhu@hotmail.com).
- Dr Fei Li, Department of Developmental and Behavioral Pediatric & Child Primary
- 29 Care, Brain and Behavioral Research Unit of Shanghai Institute for Pediatric Research,
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
- 200092, China (feili@shsmu.edu.cn).

Abstract

 There has been uncertainty regarding the long-term impact of puberty timing on human plasma metabolites. This lack of clarity can be attributed to the influence of confounding factors present in conventional observational studies. To determine the causal effect of puberty timing on plasma metabolites, we employed a two-sample Mendelian randomization (MR) analysis, complemented by MR mediation analysis assessing the direct effect. We utilized data from a large-scale meta-analysis of genome-wide association studies (GWAS) on puberty timing, consisting of 329,345 women of European ancestry, and a meta-analysis ofGWAS on plasma metabolites, involving up to 86,507 individuals. Our findings provide moderate evidence supporting a causal effect of puberty timing on 23 out of 174 plasma metabolites. After excluding 7 single nucleotide polymorphisms (SNPs) related to birth weight and childhood adiposity, causal effects remained for 16 metabolites. Through two-step MR analysis, we observed strong evidence that adulthood adiposity mediated the 47 causal relationships of puberty timing on 35 plasma metabolites. We also observed moderate evidence for an independent causal effect of puberty timing on 10 metabolites through multivariable MR analysis. We further used metabolomic data measured in the UK Biobank (UKB) to perform a replicationanalysis to validate the causal effect estimated. Nine amino acids were identified in the UKB, and the replication analysis supported our main findings.

Introduction

 The onset of puberty, influenced by a combination of genetic and environmental $\frac{1}{2}$, plays a pivotal role in shaping growth and development throughout an individual's lifespan³. Early puberty onset has been associated with various

 A recent MR study investigated if puberty timing has a distinct influence on adulthood 80 . cardiometabolic traits . The results suggested that the effects of puberty timing on

 adulthood adiposity and cardiometabolic traits are not likely driven by itself but by childhood adiposity. Additionally, it is worth noting that the majority of the cardiometabolic characteristics examined in this study mostly focused on lipids, resulting in a very restricted range of metabolites investigated. Consequently, in this 85 study, we aimed to examine whether puberty timing is likely to, directly and/or indirectly, impact a wide range of plasma metabolites, including amino acids, biogenic amines, acylcarnitines, phosphatidylcholines, lysophosphatidylcholines, sphingomyelins, and hexose in adulthood in a two-sample MR framework. Along with conducting univariable MR analysis to infer the total effect of puberty timing on plasma metabolites, we also performed MR mediation analysis to take the mediating effect of adulthood adiposity into account.

Results

Lifelong causal effects ofpuberty timing on human metabolites

 The study design is illustrated in **Fig 1**. In the primary analysis, all genetically significant SNPs were used as instrument variables. Additionally, to minimize the bias arising from horizontal pleiotropy, a secondary analysis was also performed by 97 excluding SNPs that were genetically associated with confounders (e.g., birth weight and childhood adiposity) (**Fig 2**). Two-sample MR analysis suggested moderate causal associations between genetically predicted puberty timing and 23 plasma metabolites within the subclasses including acylcarnitines, amino acids, biogenic amines, and lysophosphatidylcholines based on the primary analysis (i.e., inverse- variance weighted (IVW) analysis) results (**Fig 3-4; Table S7**) with *P* values ranging 103 from 9.09×10^{-4} to 4.92×10^{-2} . The MR analysis results supported positive causal associations oflater puberty timing with higher levels of20 metabolites. The strongest

112 For the 23 metabolites indicating moderate causal consequences of puberty timing,

113 causal effect estimates in sensitivity analyses were broadly consistentwith the results

114 of the primary IVW analysis (**Table S8-S9**). Of note, intercept terms estimated in the

115 MR-Egger regression analysis suggested that some of the results might be biased by

116 horizontal pleiotropy including aspartate, phenylalanine, alpha-aminoadipic acid,

117 lysoPC a C16:0, PC aa C38:0 and PC aa C40:1, which was also supported by

118 evidence of heterogeneity tested via Cochran's Q statistic in the IVW analysis (**Table**

119 **S10-S11**).

120 After excluding 7 SNPs associated with birth weight and childhood body mass index

121 (BMI), the secondary IVW analysis confirmed moderate evidence for causal

122 associations of later puberty timing with higher levels of 16 metabolites out of the

123 aforementioned 23 metabolites in the primary two-sample MR analysis. It is

124 noteworthy that 3 additional metabolites, including dodecenoylcarnitine: beta $= 0.06$,

125 95% CI: 2.75×10^{-3} to 1.10×10^{-2} , $P = 3.94 \times 10^{-2}$; tryptophan: beta = 0.04, 95% CI:

126 5.61×10^{-3} to 8.25×10^{-2} , $P = 2.47 \times 10^{-2}$; and kynurenine: beta = 0.06, 95% CI: 1.57

 127×10^{-2} to 9.58×10^{-2} , $P = 6.38 \times 10^{-3}$, appeared to be impacted by puberty timing in

128 the secondary IVW analysis, after controlling for potentially horizontal pleiotropic

Mediation analysis

138 The estimated causal effects of adulthood BMI on 174 metabolites suggested that 139 adulthood BMI strongly influenced plasma concentrations of some metabolites through two-step MR analysis, including 35 metabolites reaching nominal significance and 13 reaching statistical significance afterthe multiple testing Bonferroni correction (**Table S15**). Further, we found a causal effect of puberty timing (beta = -0.13, 95% CI: -0.17 to -0.09, $P = 8.71 \times 10^{-12}$) on the mediator (i.e., adulthood BMI). By exploiting the "product of coefficients" method, we derived the 145 indirect effects of puberty timing on each plasma metabolite (**Table S15**). For instance, we found that each year of delayed puberty onset was associated with 0.01 147 SD units increase in serine through the pathway of adulthood adiposity (beta = 0.01, 148 95% CI: 1.04×10^{-3} to 2.44×10^{-3} , *P* = 0.03), indicating that adulthood adiposity was a putative factor that mediated the causal relationships of puberty timing on certain metabolites. To further rule out the influence of horizontal pleiotropy, we removed a total of 13 SNPs highly related to childhood adiposity and birth weight from adulthood BMI and puberty timing genetic instrument sets. A total of 31 metabolites

 reached nominal significance and 8 reached the multiple testing Bonferroni corrected significance level. Moreover, the effect size of puberty timing on adulthood adiposity 155 attenuated from -0.13 kg/m² to -0.09 kg/m² (beta= -0.09, 95% CI: -0.11 to -0.06, *P* = 1.81×10^{-8}). Nevertheless, the mediating role of adulthood BMI between puberty timing and adulthood metabolites persisted when the potential pleiotropic effects were adjusted for (**Table S17**). The MVMR analysis results supported causal evidence for direct causal effects of puberty timing on 10 metabolites (i.e., carnitine, dodecanedioylcarnitine, hydroxytetradecenoylcarnitine, tigylcarnitine, lysine, ornithine, cis-hydroxyproline, trans-hydroxyproline, lysoPC a C20:4, and PC aa C40:4) based on nominal significance threshold of *P* < 0.05. Moreover, among the 10 significant metabolites, the results suggested that carnitine, dodecanedioylcarnitine, tigylcarnitine (acylcarnitines), lysine (amino acids), and lysoPC a C20:4 (lysophosphatidylcholines) were directly affected by puberty timing and had the same direction as results in the primary analysis (**Fig 5; Table S16**). Notably, the effect sizes attenuated to varying degrees, because adulthood BMI was adjusted for in the MVMR analysis. For example, the coefficient for dodecanedioylcarnitine attenuated from 0.11 SD units to 0.07 SD units per year later onset of puberty, approximately half of the original estimate. Compared with the results in the primary MR analysis, except for phenylalanine and tyrosine (amino acids) which showed inconsistent directions, the remaining 21 metabolites showed the same direction as the primary two-sample MR analysis. Furthermore, the MVMR analysis suggested that the plasma levels of 17 metabolites (i.e., hydroxyhexadecenoylcarnitine, nonaylcarnitine, valerylcarnitine, asparagine, aspartate, methionine, phenylalanine, serine, threonine, tyrosine, sarcosine, trans-hydroxyproline, lysoPC a C16:0, lysoPC a C17:0, lysoPC a C18:0, lysoPC a

 C18:1, lysoPC a C18:2) were mediated by adulthood BMI rather than directly affected by puberty timing (**Table S16; Table S18**).

Replication analysis

 We attempted to replicate the effect estimates for puberty timing on the identified nine metabolites in the UKB. In the two-sample MR analysis, a nominally significant causal relationship was revealed between puberty timing and two amino acids, namely 184 phenylalanine (beta = -0.03, 95% CI: -5.38 \times 10⁻² to -2.45 \times 10⁻³, $P = 3.18 \times 10^{-2}$) and 185 valine (beta = -0.04, 95% CI: -6.54 \times 10⁻² to -3.82 \times 10⁻³, $P = 2.77 \times 10^{-2}$, although 186 none of the nine amino acids reached the strictly adjusted *P* threshold of 5.56×10^{-3} (0.05/9) (**Fig 6; Table S19**). Causal effect estimates in the replication analysis of the UKB data were consistent with those estimated in the primary two-sample MR analysis except for isoleucine and glutamine. Notably, consistent with the primary MVMR analysis results, in the MVMR analysis using the UKB data, the causal effects attenuated towards null after adjusting for adulthood adiposity, suggesting little direct effects were observed between puberty timing and the nine amino acids (**Fig 6; Table S20**).

Discussion

195 Plasma levels of metabolites have been investigated as promising biomarkers for disease risk stratification and critical molecular targets for developing novel 197 treatments and interventions for a range of diseases and conditions $17-20$. Given that puberty timing is consistently associated with the risk of developing various chronic 199 diseases in adulthood 2^1 , further causal insights into the relationship between puberty 200 timing and plasma levels of metabolites will help understand underlying biological

 mechanisms and identify possible putative target biomarkers for disease treatment or intervention. Here, we systematically and extensively investigated the lifelong 203 impacts of puberty timing on human plasma metabolic profiles, by integrating data on human puberty timing and plasma metabolism in the MR causal inference framework. Genetically predicted puberty timing appeared to have causal effects on 23 plasma metabolites in adulthood. After considering the potential mediating role of adulthood 207 adiposity, direct causal effects of puberty timing on 10 adulthood metabolites 208 remained, suggesting the causal effects of puberty timing on certain metabolites in adulthood were mediated by adulthood adiposity. Our findings in the primary MR analysis were further supported by the results from the mediation analysis and external replication analysis in the UKB. Among the 23 plasma metabolites identified in the two-sample MR analysis, seven belong to acylcarnitines. In MVMR analysis, 5 of the 10 metabolites affected by 214 puberty timing were also confirmed within the subclass of acylcarnitines, including carnitine, tigylcarnitine (short-chain), dodecanedioylcarnitine, hydroxytetradecenoylcarnitine, and octadecenoylcarnitine (medium- and long-chain). With the causaleffect estimates ranging from 0.05 SD to 0.07 SD per year of delayed puberty onset, our findings suggested that certain acylcarnitine metabolites were directly and independently impacted by puberty timing. Acylcarnitines were a group of compounds formed from carnitine and acyl-CoAs in mitochondria or peroxisomal 221 by carnitine acyltransferases $22,23$, which can cross mitochondrial and cell membranes. Short-chain acylcarnitines are generated from the degradation of glucose, amino acids, and fatty acids. Medium- and long-chain acylcarnitines are largely produced from fatty acids participating in the transportation of fatty acids for the following fatty acids oxidation 24 . It has been well understood that increased plasma levels of acylcarnitine

226 are associated with a higher risk of cardiovascular disease $25-27$. The underlying mechanism might be the accumulation of acylcarnitine was associated with a 228 disturbed β-oxidation rate and mitochondrial dysfunction $28,29$. In addition, previous studies have shown that a shorter reproductive lifespan is associated with an increased 230 risk of cardiovascular disease events . Furthermore, in our study, we found a positive causal effect of delayed puberty timing on the accumulation of acylcarnitine. Taking together, our findings may shed new light on the correlation between puberty timing and cardiovascular diseases. However, whether puberty timing affects cardiovascular diseases through the acylcarnitine metabolism pathway has not been illuminated, thus more studies are warranted. Of note, we found 8 amino acids in adulthood were significantly impacted by puberty timing in the primary MR analysis, among which inverse causal effects of puberty timing on the concentrations of tyrosine and phenylalanine were externally validated using data from the UKB. After accounting for adulthood adiposity in the MVMR 240 analysis, the direct causal effects of puberty timing on these 8 amino acids attenuated to null in both the primary and replication MVMR analysis. It suggests a mediating role of adulthood adiposity in the causal pathway from puberty timing to the 243 aforementioned amino acids. Our findings were partly consistent with the findings

244 from a previous study , where an inverse association between age at menarche and

phenylalanine measured at 18 years old was revealed in the conventional

observational analysis among the females in the Avon Longitudinal Study of Parents

and Children (ALSPAC), but a causal association was failed to be established in the

one-sample MR analysis using the same ALSPAC cohort data.

 In our two-step MR analysis, we found that adulthood BMI influenced the levels of35 metabolites, and adulthood BMI itself was also influenced by puberty timing. After adjusting for adulthood BMI through MVMR analysis, the number of metabolites influenced by puberty timing decreased from 23 to 10. Our findings suggested that adulthood BMI may serve as a mediator between puberty timing and plasma metabolites. The reason lies in the fact that early-maturing individuals may face a higher risk of obesity and exhibit a higher likelihood of metabolic abnormalities in 256 adulthood . Obesity can also significantly increase the risk of developing metabolic 257 disorders by affecting energy metabolism and altering pathways , which could be the reason for changes in acylcarnitine and amino acid metabolism. The strengths of this study were as follows. First, the data we used were curated from the latest and largest GWAS in European ancestry. Second, the MR mediation analysis 261 makes it possible to infer the direct and indirect effects of genetically predicted puberty timing on adulthood plasma levels of metabolites. In the two-step MR analysis, we used adulthood BMI as a mediator to investigate the indirect effects of puberty timing on metabolites. As for MVMR analysis, we included both adulthood BMI and puberty timing as exposures to explore the direct effect of puberty timing on metabolites. Third, to minimize the risk of bias due to horizontal pleiotropy, we 267 excluded SNPs that had genome-wide significant associations with birth weight or childhood obesity. Finally, external replication analysis using data from the UKB supported our primary analysis results, suggesting the robustness of our findings. Limitations were also noted. First, our study results were primarily based on GWAS

271 conducted in individuals of European descent. Consequently, it should be cautious when generalizing the results to non-European populations. Second, despite extensive

 analyses were performed to minimize the risk of bias due to horizontal pleiotropy, it cannot be fully ruled out, thus the results should be interpreted with caution. Third, the puberty timing GWAS were conducted in females exclusively, while the metabolites GWAS included female and male individuals. As there may be sex- specific effects on the levels of metabolites 33 , this could potentially impact our causal effect estimates. Thus, future studies taking into account the sex-specific effects with regard to the relationship between puberty timing and human plasma metabolism are warranted.

In summary, we explored the causal relationship of puberty timing with human

plasma metabolite levels using publicly available GWAS summary data. We found a

causal effect of puberty timing on 23 plasma metabolites through two-sample MR

analysis, and most of the effects were mediated by adulthood adiposity. The findings

285 provide novel insights into the causal inferences of puberty timing on human

metabolism. Additionally, the role of adulthood adiposity in mediating the causal

relationship between puberty timing and plasma metabolites is identified.

Material and Methods

Data sources

The information on all GWAS data used in the analyses is shown in **Table S21**.

Summary statistics on age at menarche (AAM) (measured in years) were obtained

- from the largest meta-analysis of GWASs, including 329,345 women of European
- 293 ancestry from 42 cohort studies . A total of 389 SNPs reaching genome-wide
- 294 significance $(P < 5 \times 10^{-8})$ were identified. There exists a genetic correlation $(r_g=0.74)$
- between the AAM of females and the age at voice breaking of males, which suggests

296 thatmany genetic variants have comparable effects on puberty timing in both males 297 and females. Consequently, there was credibility that genetic variants ofAAM can 298 provide confident insights into puberty timing in males as well 35 . Thus, in our study, 299 these genetic variants were considered instrumental variables for puberty timing. We 300 also refer to AAM as puberty timing in the present study. 301 A total of 174 plasma metabolites in seven biochemical categories (i.e., amino acids, 302 biogenic amines, acylcarnitines, phosphatidylcholines, lysophosphatidylcholines, 303 sphingomyelins, and hexoses), from the largest GWAS of human plasma metabolites, 304 were used as the outcomes in this study 36 . Summary statistics on all metabolites 305 measured by high-throughput platforms were obtained from the cross-platform meta-306 analysis GWAS of blood metabolites, which included several cohorts with sample 307 sizes for each metabolite ranging from 8,569 to 86,507 individuals of European 308 ancestry. The GWASs were undertaken in cohorts of Fenland study ($N = 9.363$), 309 EPIC-Norfolk (European Prospective Investigation into Cancer-Norfolk) ($N = 5,841$), 310 and INTERVAL study (Metabolon Discovery HD4 platform, $N = 8,455$ and ¹H 311 nuclear magnetic resonance (NMR), Nightingale, $N = 40,905$). The results were 312 further meta-analyzed with two published studies conducted by Kettunen et al. $(N =$ 313 24,925) and Shin et al. $(N = 7,824)$ 37,38. 314 The adulthood adiposity GWAS conducted by the Genetic Investigation of

315 Anthropomorphic Traits (GIANT) consortium included 315,347 adults of European

316 ancestry, combining data from the Research Program on Genes, Environment, and

317 Health (RPGEH), Genetic Epidemiology Research on Aging (GERA) cohort and a

318 meta-analysis of GWASs conducted by Locke et al. ^{39,40}. A total of 147 genome-wide

significant variants associated with adulthood BMI were selected as genetic

instruments in the MR mediation analysis.

332 We then attempted to replicate the findings of our study by using data from

independent GWASs. Data on puberty timing were obtained from a GWAS conducted

334 on up to 182,416 females of European descent from 58 studies ⁴⁵. Summary statistics

on adulthood BMI were obtained from a meta-analysis of 322,154 European

336 ancestries from the GIANT consortium ⁴⁰. Furthermore, we obtained summary

statistics from a GWAS of metabolites measured in the UKB, which were conducted

338 . on over $114,000$ individuals of European ancestry 46 .

Genetic instruments selection

To ensure statistical independence between genetic instruments, we performed a

341 stringent linkage disequilibrium (LD) clumping (window = 10 MB and r^2 < 0.001 in

Statistical analysis

Two-sample MR analysis

 As shown in **Fig 1**, a two-sample MR analysis wasused as the primary analysis 357 approach to examine the causal effects of genetically predicted puberty timing on 174 human plasma metabolites. The IVW method, which assumes no correlations or interactions between genetic instruments and generates average causal effect estimates across multiple instruments, was used in the primary MR analysis 48 . The causal effect estimates were interpreted as standardized mean differences in concentrations of metabolites per year delayed onset of puberty. Heterogeneity between causal effect estimates for each SNP was examined by calculating Cochran's Q statistic, which indicated potentially horizontal pleiotropy.

MR mediation analysis

Sensitivity analysis

 To assess the robustness of our results in the two-sample MR analysis, we also performed four other sensitivity analyses. MR-Egger regression provides an unbiased estimate of the causal effect even if all SNPs used as instrumental variables are invalid

- 410 UKB were identified to coincide with the metabolites included in the primary analysis,
- 411 we merely estimated the relationship between puberty timing and the nine amino

Multiple testing correction

multiple-test correction was applied. The *P* value threshold for statistical significance

423 becomes $P < 4.90 \times 10^{-4}$ (0.05/102) after correcting for 102 tests corresponding to the

424 number of principal components explained 95% of the variance of the 174 metabolites

425 in the GWAS by Lotta et al. , which indicated strong causal evidence for our results.

Meanwhile, the conventional *P* value threshold of 0.05 was also reported to avoid

ignoring potentially crucial findings after constructing a "suggestive significance

428 threshold" ^{60,61}, which offered moderate causal evidence.

All statistical analyses were performed using R version 4.1.2, in which the

TwoSampleMR (version 0.5.6) and MRPRESSO (version 1.0) packages were used

 . $47,56$. The ggpolt2 and circlize R packages were used to visualize statistical analysis 432 results ^{62,63}.

Data availability

The genetic instruments for puberty timing were obtained from the corresponding

- literature at https://reprogen.org/data_download.html. Data on plasma metabolites
- GWAS can be found at www.omicscience.org. Full summary data on adulthood BMI
- were obtained from the MRC Integrative Epidemiology Unit OpenGWAS project
- (https://gwas.mrcieu.ac.uk/). Full summary data on birth weight and childhood BMI
- were obtained from the Early Growth Genetics Consortium (egg-consortium.org). The
- replication analyses were conducted using data from the UKB
- (https://www.ukbiobank.ac.uk/) and the summary level data were obtained at
- https://gwas.mrcieu.ac.uk/.

Code availability

444 Scripts are available on GitHub at https://github.com/ZengjunLi/Puberty metabolites.

References

- 1. Toppari, J. & Juul, A. Trends in puberty timing in humans and environmental modifiers. *Molecular and Cellular Endocrinology* **324**, 39-44 (2010).
- 2. Day, F.R., Perry, J.R.B. & Ong, K.K. Genetic Regulation of Puberty Timing in Humans. *Neuroendocrinology* **102**, 247-255 (2015).
- 3. Pinyerd, B. & Zipf, W.B. Puberty—Timing Is Everything! *Journal of Pediatric Nursing* **20**, 75-82 (2005).
- 4. Li, W. *et al.* Association between Obesity and Puberty Timing: A Systematic Review and Meta-Analysis. in *International Journal of Environmental Research and Public Health* Vol. 14 (2017).
- 5. Prentice, P. & Viner, R.M. Pubertal timing and adult obesity and cardiometabolic risk in women and men: a systematic review and meta-analysis. *International Journal of Obesity* **37**, 1036-1043 (2013).
- 6. Cheng, T.S., Day, F.R., Lakshman, R. & Ong, K.K. Association of puberty timing with type 2

-
- diabetes: a systematic review and meta-analysis. *PLoS medicine* **17**, e1003017 (2020).
- 7. Hulanicka, B., Lipowicz, A., Kozieł, S. & Kowalisko, A. Relationship between early puberty
- and the risk of hypertension/overweight at age 50: Evidence for a modified Barker hypothesis among Polish youth. *Economics & Human Biology* **5**, 48-60 (2007).
- 8. Biro, F.M., Huang, B., Wasserman, H., Gordon, C.M. & Pinney, S.M. Pubertal Growth, IGF-1,
- and Windows of Susceptibility: Puberty and Future Breast Cancer Risk. *Journal of Adolescent Health* **68**, 517-522 (2021).
- 9. Galvao, T.F. *et al.* Pubertal timing in girlsand depression: A systematic review. *Journal of Affective Disorders* **155**, 13-19 (2014).
- 10. Park, J., Shin, Y., Kim, T.H., Kim, D.-H. & Lee, A. Plasmametabolites as possible biomarkers for diagnosis of breast cancer. *PLoS One* **14**, e0225129 (2019).
- 11. Zhao, Y., Lv, H., Qiu, S., Gao, L. & Ai, H. Plasma metabolic profiling and novel metabolite biomarkers for diagnosing prostate cancer. *RSC advances* **7**, 30060-30069 (2017).
- 12. Heys, M. *et al.* Age of Menarche and the Metabolic Syndrome in China. *Epidemiology* **18**(2007).
- 13. Feng, Y. *et al.* Effects of age at menarche, reproductive years, and menopause on metabolic risk factors for cardiovascular diseases. *Atherosclerosis* **196**, 590-7 (2008).
- 14. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?*. *International Journal of Epidemiology* **32**, 1-22 (2003).
- 15. Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N. & Davey Smith, G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. *Statistics in Medicine* **27**, 1133-1163 (2008).
- 16. Bell, J. *et al.* Influence of puberty timing on adiposity and cardiometabolic traits: A Mendelian randomisation study. *PLOS Medicine* **15**, e1002641 (2018).
- 17. Yuan, B. *et al.* A plasma metabolite panel as biomarkers for early primary breast cancer detection. *International Journal of Cancer* **144**, 2833-2842 (2019).
- 18. Knific, T. *et al.* Models including plasma levels of sphingomyelins and phosphatidylcholines as diagnostic and prognostic biomarkers of endometrial cancer. *The Journal of Steroid Biochemistry and Molecular Biology* **178**, 312-321 (2018).

- 19. Li, S., Gao, D. & Jiang, Y. Function, Detection and Alteration of Acylcarnitine Metabolism in
- Hepatocellular Carcinoma. *Metabolites* **9**(2019).
- 20. Takaya, H. *et al.* Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. *World J Gastrointest Oncol* **11**, 887-897 (2019).
- 21. Day, F.R., Elks, C.E., Murray, A., Ong, K.K. & Perry, J.R. Puberty timing associated with
- diabetes, cardiovascular disease and also diverse health outcomes in men and women: the UK Biobank study. *Sci Rep* **5**, 11208 (2015).
- 22. Kerner, J. & Hoppel, C. Fatty acid import into mitochondria. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* **1486**, 1-17 (2000).
- 23. Violante, S. *et al.* Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* **1831**, 1467-1474 (2013).
- 24. Meierhofer, D. Acylcarnitine profiling by low-resolution LC-MS. *PLoS One* **14**, e0221342 (2019).
- 25. Guasch-Ferré, M. *et al.* Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions. *Am J Clin Nutr***103**, 1408-16 (2016).
- 26. Kaul, P. *et al.* Incidence of heart failure and mortality after acute coronary syndromes. *Am Heart J* **165**, 379-85.e2 (2013).
- 27. Kalim, S. *et al.* A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. *J Am Heart Assoc* **2**, e000542 (2013).
- 28. Nicholas, D.A. *et al.* Fatty Acid Metabolites Combine with Reduced β Oxidation to Activate
- Th17 Inflammation in Human Type 2 Diabetes. *Cell Metab* **30**, 447-461.e5 (2019).
- 29. Jarrell, Z.R. *et al.* Plasma acylcarnitine levels increase with healthy aging. *Aging (Albany NY)* **12**, 13555-13570 (2020).
- 30. Mishra, S.R., Chung, H.F., Waller, M. & Mishra, G.D. Duration of estrogen exposure during reproductive years, age at menarche and age at menopause, and risk of cardiovascular disease events, all-cause and cardiovascular mortality: a systematic review and meta-analysis. *BJOG:*
- *An International Journal of Obstetrics & Gynaecology* **128**, 809-821 (2021).
- 31. Richardson, T.G., Sanderson, E., Elsworth, B., Tilling, K. & Davey Smith, G. Use of genetic variation to separate the effects of early and later life adiposity on disease risk: mendelian

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295295;](https://doi.org/10.1101/2023.09.09.23295295) this version posted September 11, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

- randomisation study. *Bmj* **369**, m1203 (2020).
- 32. Zhou, Y. *et al.* Obesity and diabetes related plasma amino acid alterations. *Clinical Biochemistry* **46**, 1447-1452 (2013).
- 33. Verri Hernandes, V. *et al.* Age, Sex, Body Mass Index, Diet and Menopause Related Metabolites in a Large Homogeneous Alpine Cohort. *Metabolites* **12**(2022).
- 34. Day, F.R. *et al.* Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nat Genet* **49**, 834-841 (2017).
- 35. Day, F.R. *et al.* Shared genetic aetiology of puberty timing between sexes and with health-related outcomes. *Nature Communications* **6**, 8842 (2015).
- 36. Lotta, L.A. *et al.* A cross-platform approach identifies genetic regulators ofhuman metabolism and health. *Nat Genet* **53**, 54-64 (2021).
- 37. Kettunen, J. *et al.* Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects ofLPA. *Nat Commun* **7**, 11122 (2016).
- 38. Shin, S.Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat Genet* **46**, 543-550 (2014).
- 39. Hoffmann, T.J. *et al.* A Large Multiethnic Genome-Wide Association Study of Adult Body Mass Index Identifies Novel Loci. *Genetics* **210**, 499-515 (2018).
- 40. Locke, A.E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206 (2015).
- 41. Wang, Y., Dinse, G.E. & Rogan, W.J. Birth weight, early weight gain and pubertal maturation: a longitudinal study. *Pediatr Obes* **7**, 101-9 (2012).
- 42. Bull, C.J. *et al.* Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. *BMC Med* **18**, 396 (2020).
- 43. Warrington, N.M. *et al.* Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. *Nat Genet* **51**, 804-814 (2019).
- 44. Bradfield, J.P. *et al.* A trans-ancestral meta-analysis of genome-wide association studies reveals loci associated with childhood obesity. *Hum Mol Genet* **28**, 3327-3338 (2019).
- 45. Perry, J.R. *et al.* Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature* **514**, 92-97 (2014).
- 46. Borges, M.C. *et al.* Role of circulating polyunsaturated fatty acids on cardiovascular diseases

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295295;](https://doi.org/10.1101/2023.09.09.23295295) this version posted September 11, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

 risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. *BMC Med* **20**, 210 (2022). 47. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**(2018). 48. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* **37**, 658-65 (2013). 49. Relton, C.L. & Davey Smith, G. Two-step epigenetic Mendelian randomization: a strategy for 556 establishing the causal role of epigenetic processes in pathways to disease. *Int J Epidemiol* 41, 161-76 (2012). 50. VanderWeele, T.J. Mediation Analysis: A Practitioner's Guide. *Annu Rev Public Health* **37**, 17- 32 (2016). 51. MacKinnon, D.P., Fairchild, A.J. & Fritz, M.S. Mediation analysis. *Annu Rev Psychol* **58**, 593- 614 (2007). 52. Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* **48**, 713-727 (2019). 53. Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int J Epidemiol* **45**, 1961-1974 (2016). 54. Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* **40**, 304-14 (2016). 55. Hartwig, F.P., Davey Smith, G. & Bowden, J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *International Journal of Epidemiology* **46**, 1985-1998 (2017). 56. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nature Genetics* **50**, 693-698 (2018). 57. Bell, J.A. *et al.* Influence of puberty timing on adiposity and cardiometabolic traits: A Mendelian randomisation study. *PLoS Med* **15**, e1002641 (2018).

Acknowledgements

- This study was supported by grants from the National Natural Science Foundation of
- China (82373588, 82125032, 81930095 and 81761128035), Xinhua Hospital,
- Shanghai Jiao Tong University School of Medicine, Shanghai, China (2021YJRC02),
- Innovative research team of high-level local universities in Shanghai (SHSMU-
- ZDCX20211100), the Science and Technology Commission of Shanghai Municipality
- (19410713500 and 2018SHZDZX01), the Shanghai Municipal Commission of Health
- and Family Planning (GWV-10.1-XK07, 2020CXJQ01, 2018YJRC03) and Sichuan
- Science and Technology Program (2021JDR0189). The funders of the study had no
- role in the study design, data collection, data analysis, or data interpretation; writing
- or reviewing of the manuscript; and decision to submit the manuscript for publication.

Author information

Authors and Affiliations

- 1. Department of Epidemiology and Biostatistics, West China School of Public Health
- and West China Fourth Hospital, Sichuan University, 610041, China.
- Zengjun Li & Cairong Zhu*
- 2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
- Si Fang
- 3. Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, United Kingdom.

Si Fang

- 4. Ministry of Education and Shanghai Key Laboratory of Children's Environmental
- Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine,
- Shanghai, 200092, China
- Dong Liu, Fei Li* & Jian Zhao*
- 5. Department of Developmental and Behavioral Pediatric & Child Primary Care,
- 620 Brain and Behavioral Research Unit of Shanghai Institute for Pediatric Research,
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
- China
- Fei Li*
- 6. Department of Maternal and Child Health, School of Public Health, Shanghai Jiao Tong University, 200092, China.
- Fei Li* & Jian Zhao*

Contributions

- Cairong Zhu, Fei Li, and Jian Zhao initially conceived the study design. Zengjun Li
- and Si Fang carried out statistical analyses, and Zengjun Li wrote the first draft of the
- manuscript with input from Cairong Zhu, Fei Li, and Jian Zhao. Zengjun Li and Dong
- Liu plotted the figures.All authors contributed to the interpretation of the results and
- critical revision of the manuscript.
- **Corresponding author**

Correspondence to Jian Zhao, Cairong Zhu, and Fei Li.

Ethical approval

- This study used publicly available GWAS summary data and was not subject to
- institutional review board approval.

Competing interests

The authors declare no competing interests.

Supplementary information

Table S1-S21.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295295;](https://doi.org/10.1101/2023.09.09.23295295) this version posted September 11, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

644

646 **plasma metabolites.** The primary analysis was conducted utilizing a two-sample MR

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295295;](https://doi.org/10.1101/2023.09.09.23295295) this version posted September 11, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

 Fig 2. The directed acyclic graphs ofthe Mendelian randomization study. The figures depict directed acyclic graphs for univariable Mendelian randomization (MR) and mediation MR analysis in panel A and panel B respectively. The dashed lines represent potential horizontal pleiotropy or direct causal effects between variables, which would violate the MR assumption. MR approach is based on three assumptions: (1) the IVs (instrument variables) are strongly associated with the exposure (e.g., puberty timing); (2) the genetic IVs are not associated with any confounders (e.g., birth weight and childhood BMI (body mass index)); (3) the genetic IVs should influence the outcome (e.g., a metabolite) through the exposure independently instead of through other pathways. The primary analysis was performed, wherein SNPs that exhibited genetic associations with puberty timing were selected as IVs. To minimize the risk of bias due to horizontal pleiotropy, a secondary analysis was conducted wherein SNPs that exhibited genetic associations with birth weight and/or childhood BMI

673 were excluded.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295295;](https://doi.org/10.1101/2023.09.09.23295295) this version posted September 11, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

676 **Fig 3. Circos plot depicting the causal effect estimates ofpuberty timing on all 174** 677 **plasma metabolites.** The legend located at the lower section of the figure provides a visual 678 representation of distinct subclasses of plasma metabolites. The presence of metabolites 679 highlighted with the color blue indicates a positive causal effect of puberty timing on the 680 concentration of plasma metabolites. Specifically, each year later in puberty timing is 681 associated with higher levels of metabolites. In contrast, the identification of metabolites 682 highlighted with the color red suggests a negative causal effect of puberty timing on the 683 concentration of plasma metabolites, that is each year later in puberty timing is associated 684 with lower levels of metabolites. The presence of metabolites that had been designated as 685 black indicates that there is insufficient evidence to establish a causal relationship. The

- 686 evidence indicates a causal effect of puberty timing on 23 plasma metabolites. Error bars
- 687 represent 95% confidence intervals. All statistical tests were two-sided.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295295;](https://doi.org/10.1101/2023.09.09.23295295) this version posted September 11, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

690 **metabolites.** The legend located on the right side of the forest plot indicates different analysis

- 691 approaches. Plasma metabolites reaching nominal significance $(P < 0.05)$ were shown
- 692 according to the results of IVW (inverse-variance weighted). The results presented on the left

 side of the plot were analyzed using the IVW approach. The colors represent green, using the IVW method to estimate the effect size of puberty timing on plasma metabolites; blue; using the IVW method, but excluding 7 genetic instruments genetically related to birth weight and/or childhood BMI (body mass index). The results presented on the right were derived from four distinct sensitivity analyses. The sensitivity analysis findings indicate that the results ofthe primary analysis are largely robust. Error bars represent 95% confidence intervals. All statistical tests were two-sided. The metabolites were divided according to different subclasses. AA amino acids; AC acylcarnitines; BA biogenic amines; LPC

lysophosphatidylcholines.

 Fig 5. Forest plots comparing the effect estimates ofpuberty timing and adulthood BMI on plasma metabolites in MVMR analyses. The legend located on the right side of the 705 forest indicates the distinct analysis. Plasma metabolites reaching nominal significance $(P \leq$ 706 0.05) in puberty timing were shown according to the results of the MVMR (multivariable Mendelian randomization) approach. The colors represent blue, using the MVMR method to estimate the effect size of puberty timing or adulthood BMI on plasma metabolites; purple; using the MVMR method, but excluding 8 genetic instruments associated with birth weight and/or childhood BMI (body mass index). The results on the left show the effect size of puberty timing on each plasma metabolite, whereas the results on the right present the effect size of adulthood BMI on each plasma metabolite. Error bars represent 95% confidence intervals. All statistical tests were two-sided. The metabolites were also divided according to different subclasses. AA amino acids; AC acylcarnitines; BA biogenic amines; LPC lysophosphatidylcholines; PC phosphatidylcholines.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.09.09.23295295;](https://doi.org/10.1101/2023.09.09.23295295) this version posted September 11, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

 Fig 6. Forest plots comparing the effect estimates ofpuberty timing on nine amino acids in replication analyses. The legend located on the right side of the forest plot indicates 720 different analysis methods. The results of two-sample MR (Mendelian randomization) and MVMR (multivariable Mendelian randomization) represented the total (blue) and direct impact (orange) of puberty timing on plasma metabolites, respectively. To inspect the robustness of our two-sample MR and MVMR analysis results (purple and green), we 724 estimated the causal relationship of puberty timing on nine identified amino acids using data from the UKB (UK Biobank). Our findings in the primary MR analysis were further supported by the findings from external replication analysis in the UKB. Error bars represent 95% confidence intervals. All statistical tests were two-sided.